Steroid minimization in nephrotic syndrome relapses
Related Experiment Video
Updated: Nov 6, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
1Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Abstract:
Corticosteroids remain the cornerstone of therapy for nephrotic syndrome (NS), yet cumulative exposure from repeated treatment courses during relapses contributes to substantial short- and long-term toxicity. Although several controlled trials have examined corticosteroid-sparing strategies, including reduced doses, shortened treatment durations, and single-dose regimens, robust evidence to define the optimal corticosteroid regimen for relapse management remains limited. Well-powered, high-quality randomized controlled trials are needed to establish standardized, evidence-based approaches to relapse treatment. This review summarizes current evidence on corticosteroid dosing strategies and proposes approaches to minimize corticosteroid exposure in children with relapsing NS. Future directions incorporating biomarkers, pharmacogenomics, artificial intelligence, and improved assessment of hypothalamic-pituitary-adrenal axis recovery may enable a more personalized approach to corticosteroid therapy in this population.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Chronic Kidney Disease III: Interprofessional Care
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant